Literature DB >> 9378815

CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells.

D Govender1, P Harilal, M Dada, R Chetty.   

Abstract

AIMS: To investigate the immunohistochemical expression of CD31 (JC70) in normal and neoplastic plasma cells.
METHODS: Plasma cells in bone marrow biopsies and extramedullary locations were examined. All extramedullary biopsies were formalin fixed and paraffin embedded. The bone marrow biopsies were fixed in formal acetic acid and embedded in paraffin wax. Twenty multiple myelomas (12 bone marrow and eight extramedullary deposits), 10 extramedullary plasmacytomas, and 30 biopsies with reactive plasma cells (10 bone marrow, 20 extramedullary biopsies) were stained with anti-CD31 (JC70) using the streptavidin-biotin detection system with diaminobenzidine as a chromogen. Antigen retrieval in bone marrow biopsies was achieved by pressure cooking. In all other biopsies, antigen retrieval was achieved by microwave pretreatment.
RESULTS: All 20 extramedullary cases with reactive plasma cells showed intense membrane staining. Focal staining was detected in reactive plasma cells in bone marrow biopsies. Five of 10 plasmacytomas showed membrane staining. None of the cases of multiple myeloma, either medullary or extramedullary, showed any immunoreactivity for CD31.
CONCLUSIONS: CD31, a member of the immunoglobulin supergene family of cell adhesion molecules, is strongly expressed in extramedullary reactive plasma cells, focally in bone marrow reactive plasma cells, and occasionally in extramedullary plasmacytomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378815      PMCID: PMC499981          DOI: 10.1136/jcp.50.6.490

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections.

Authors:  D V Parums; J L Cordell; K Micklem; A R Heryet; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

Review 2.  Morphoregulatory molecules.

Authors:  G M Edelman
Journal:  Biochemistry       Date:  1988-05-17       Impact factor: 3.162

Review 3.  The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion.

Authors:  S O Wawryk; J R Novotny; I P Wicks; D Wilkinson; D Maher; E Salvaris; K Welch; J Fecondo; A W Boyd
Journal:  Immunol Rev       Date:  1989-04       Impact factor: 12.988

4.  Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing.

Authors:  B A Cunningham; J J Hemperly; B A Murray; E A Prediger; R Brackenbury; G M Edelman
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

5.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

Authors:  M J Elices; L Osborn; Y Takada; C Crouse; S Luhowskyj; M E Hemler; R R Lobb
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

6.  Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).

Authors:  B Van Camp; B G Durie; C Spier; M De Waele; I Van Riet; E Vela; Y Frutiger; L Richter; T M Grogan
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

7.  PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily.

Authors:  P J Newman; M C Berndt; J Gorski; G C White; S Lyman; C Paddock; W A Muller
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

8.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule.

Authors:  S Benchimol; A Fuks; S Jothy; N Beauchemin; K Shirota; C P Stanners
Journal:  Cell       Date:  1989-04-21       Impact factor: 41.582

9.  Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Authors:  C Pellat-Deceunynck; S Barillé; D Puthier; M J Rapp; J L Harousseau; R Bataille; M Amiot
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

10.  A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions.

Authors:  W A Muller; C M Ratti; S L McDonnell; Z A Cohn
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  5 in total

1.  Plasmablastic plasmacytoma of the breast.

Authors:  Don K Le; David Metter; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

2.  Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma.

Authors:  Genevieve M Crane; Rena R Xian; Kathleen H Burns; Michael J Borowitz; Amy S Duffield; Janis M Taube
Journal:  J Cutan Pathol       Date:  2014-12-08       Impact factor: 1.587

3.  Breast tumor microenvironment structures are associated with genomic features and clinical outcome.

Authors:  Esther Danenberg; Helen Bardwell; Vito R T Zanotelli; Elena Provenzano; Suet-Feung Chin; Oscar M Rueda; Andrew Green; Emad Rakha; Samuel Aparicio; Ian O Ellis; Bernd Bodenmiller; Carlos Caldas; H Raza Ali
Journal:  Nat Genet       Date:  2022-04-18       Impact factor: 41.307

4.  CD138 and CD31 Double-Positive Cells Comprise the Functional Antibody-Secreting Plasma Cell Compartment in Primate Bone Marrow.

Authors:  Paola Martinez-Murillo; Lotta Pramanik; Christopher Sundling; Kjell Hultenby; Per Wretenberg; Mats Spångberg; Gunilla B Karlsson Hedestam
Journal:  Front Immunol       Date:  2016-06-27       Impact factor: 7.561

5.  Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.

Authors:  Pulathis N Siriwardana; Tu Vinh Luong; Jennifer Watkins; Helen Turley; Mohamed Ghazaley; Kevin Gatter; Adrian L Harris; Daniel Hochhauser; Brian R Davidson
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.